Neuronal migration defects, including pachygyria, are among the most severe developmental brain defects in humans. Here, we identify biallelic truncating mutations in CTNNA2, encoding α N-catenin, in patients with a distinct recessive form of pachygyria. CTNNA2 was expressed in human cerebral cortex, and its loss in neurons led to defects in neurite stability and migration. The α N-catenin paralog, α E-catenin, acts as a switch regulating the balance between β -catenin and Arp2/3 actin filament activities 1 . Loss of α N-catenin did not affect β -catenin signaling, but recombinant α N-catenin interacted with purified actin and repressed ARP2/3 actinbranching activity. The actin-binding domain of α N-catenin or ARP2/3 inhibitors rescued the neuronal phenotype associated with CTNNA2 loss, suggesting ARP2/3 de-repression as a potential disease mechanism. Our findings identify CTNNA2 as the first catenin family member with biallelic mutations in humans, causing a new pachygyria syndrome linked to actin regulation, and uncover a key factor involved in ARP2/3 repression in neurons.
The lissencephaly (LIS) spectrum is characterized by defects in the folding pattern of the cerebral cortex, resulting in reduced numbers or complexity of gyri that characterize the human brain 2 . LIS encompasses a continuum of malformations ranging from complete agyria to pachygyria, in which gyral formation is diminished but not absent. Patients present clinically with failed motor and cognitive development followed by intractable epilepsy. Most patients are severely intellectually impaired, and are unable to walk or care for themselves.
Projection neurons of the cerebral cortex are born in a zone adjacent to the ventricle, then migrate to the future six-layered neocortex. Neuronal migration is achieved through a rearrangement of cytoskeletal components in response to extracellular cues, mediated by numerous intracellular signaling pathways 3 . Coordinated regulation of monomeric (G-actin) and polymerized actin microfilaments (F-actin) is critical for neuronal growth cone morphogenesis, axon pathfinding, and neurite extension during migration 4, 5 . Positive regulators of F-actin assembly include families of nucleating proteins (formins and Arp2/3) and their co-activators (Rho GTPases, and Letters NATuRE GENETics the Wiskott-Aldrich syndrome family proteins WASP and WAVE), but negative regulators remain elusive, particularly in neurons 6 .
We recruited three families, with seven affected individuals showing neurodevelopmental delay ( Fig. 1a and Table 1 ). All were diagnosed before the age of two years and displayed acquired microcephaly, hypotonic cerebral palsy, inability to ambulate or speak, and intractable seizures ( Table 1) . Magnetic resonance imaging (MRI) demonstrated pachygyria with dramatic cortical gray matter thickening up to 3-4 cm, with a paucity of gyri without an obvious posterior-anterior gradient or focal dysplasias. There was absent anterior commissure, hypogenesis of the corpus callosum, and cerebellar hypoplasia (Fig. 1b ). This phenotype is distinct from LIS1-pachygyria or DCX-pachygyria, which show posterior or anterior gradients, respectively. All subjects were enrolled using Institutional Review Board-approved protocols and provided consent for the study. We performed whole-exome sequencing 7 on at least one member of each family 8 . We prioritized rare (< 0.2% allele frequency) damaging variants (genomic evolutionary rate profiling score > 4 or sorting intolerant from tolerant score < 0.05) and focused on homozygous variants due to parental consanguinity. Parametric linkage analysis from genome-wide SNP arrays and homozygosity mapping 9,10 showed identical-by-descent haplotypes ( Supplementary Fig. 1a ). Aligning variants with corresponding homozygous intervals identified putative nonsense variants in 
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CTNNA2 in all three families (family 1101: c.2664C> T, p.Arg882*; family 1263: c.2341C> T, p.Arg781*; family 4727: c.1480C> T, p.Arg494*) ( Fig. 1c,d and Supplementary Fig. 1b ). The three variants were each observed once, only heterozygous, in the public databases Exome Aggregation Consortium (ExAC) and Genome Aggregation Database (gnomAD). Sanger sequencing confirmed segregation according to a strict recessive mode of inheritance, with full penetrance, in all genetically informative available family members, suggesting that biallelic CTNNA2 loss-of-function mutations underlie pachygyria in these patients. CTNNA2 is the ancestral α -catenin gene and is conserved in all Metazoa, but is predominantly expressed in the brain in mammals 11 . CTNNA1 is the most widely expressed, but is absent from populations of migrating neurons 12 , whereas CTNNA3 is expressed predominantly in the myocardium. We confirmed CTNNA2 expression in human neural tissue ( Supplementary Fig. 2a ), and found protein co-expression with the migration markers Dcx and Tuj1 in the murine embryonic day E13.5 brain ( Supplementary Fig. 2b ). As reported in the mouse, a rim of α N-catenin was expressed in the apically localized progenitors of the ventricular zone 12 . In 20-weekgestation human fetal brain, α N-catenin was mostly restricted to regions expressing DCX and TUJ1 in the developing cortical plate and marginal zone ( Supplementary Fig. 2c ).
There are two mouse lines harboring loss-of-function mutations of the ortholog to human CTNNA2 (Catna2). Cerebellar deficient folia (cdf) mice have a spontaneous carboxy (C)-terminal deletion [13] [14] [15] , and the conventional knockout removed the first exon 16 . These mutants share multiple phenotypes, including impaired lamination of a subset of Purkinje and hippocampal neurons [13] [14] [15] [16] , hippocampal dendritic spine morphogenesis 16, 17 , axon projections, positioning of subsets of nuclei-specific neurons, and midline axonal crossing 18 . Of note, many of the phenotypes present in Catna2 mice are shared with CTNNA2 patients, including cerebellar hypoplasia and midline defects; however, neither line showed evidence of an overt neocortical phenotype 15 . This was not surprising given that mouse models for human cortical migration defects typically show no neocortical defects.
To investigate migration in a human model, we generated induced pluripotent stem cells (iPSCs) and neuronal derivatives from the affected and unaffected members of family 1263 (1263A and the control, respectively) and an individual with LIS due to Miller-Dieker syndrome (MDS; deletion of chromosome 17p11.3), as well as targeting the CTNNA2 gene in the H9 human embryonic stem cell (hESC) line (herein referred to as CTNNA2 KO ) 19 ( Supplementary Fig. 3 ). Western blot of the neuronal progenitor cells (NPCs) demonstrated absent α N-catenin protein in the patient and knockout compared with the control ( Supplementary Fig. 4 ).
To study migration, we adopted a neurosphere assay 20 , and measured neuronal cell body distances from the edge after 48 h. First, we confirmed that cells exiting the neurosphere expressed postmitotic neuronal markers and were negative for other lineages ( Supplementary Fig. 5a ,b). Glial fibrillary acidic protein-positive cells were only observed at the edge of the plated spheres in all of the lines tested ( Supplementary Fig. 5a ,b). Cell bodies of control neurons showed a migration front at 514 µ m ( Fig Consistent with what has been observed in MDS and control cerebral organoid models of neuronal migration 21 , the distribution of distances of MDS, CTNNA2 patients, and CTNNA2 KO exited neurons was significantly reduced ( Fig. 2a and Supplementary Figs. 6 and 7). We conclude that loss of CTNNA2 results in a neuronal migration defect in vitro.
Time-lapse phase microscopy was performed to study the mechanism of defective migration. Control cells displayed bipolar morphology, with an average leading neurite length of 130 μ m. CTNNA2-mutant cells showed shortened (average length: 18 μ m) disorganized leading processes, enlarged growth cones, proximal ectopic filopodia and lamellipodia, and failed bipolar morphology ( Fig. 2b and Supplementary Videos 1-3). We confirmed that the neurite length and migration defect were due to the absence of CTNNA2 using lentiviral transduction rescue with green fluorescent protein (GFP)-tagged CTNNA2. Transduced cells had uniform expression of a full-length α N-catenin-GFP at 129 kDa and a processed product at 102 kDa ( Supplementary Fig. 8a ). Neurite length and migration were largely restored in both patient and CTNNA2 KO cells upon CTNNA2-GFP forced expression ( Fig. 2b,c and Supplementary Figs. 6 and 7).
Previous studies have shown that mouse α E-catenin, encoded by Catna1, is required for preimplantation epithelial integrity 22 , whereas conditional deletion in the embryonic brain disrupts adherens junctions, leading to dysregulated proliferation 23 . To test whether loss of CTNNA2 affects neuroepithelium polarity, we generated neural rosettes from the control and 1263A iPSCs and used immunostaining to examine apical polarization. Despite the absence of α N-catenin at the apical surface of the rosette, the tight junction marker zonula occludens-1 and the adherens junction markers N-cadherin and β -catenin were localized in a polarized fashion near cilia ( Supplementary Fig. 9 ). These results suggest that loss of CTNNA2 does not adversely affect apical polarization of neuroepithelial cells in culture.
The presence of a putative β -catenin binding domain suggests α N-catenin loss may alter Wnt signaling 24 . We therefore compared gene expression profiles between MDS, 1263A and control NPCs by RNA sequencing. We found no consistent, differential expression changes, arguing against a major transcriptional effect ( Supplementary Fig. 10a -c). Furthermore, established canonical Wnt target genes were not changed ( Supplementary Fig. 10d ), suggesting that the loss of CTNNA2 does not measurably impact Wntmediated transcription.
We thus focused on potential α N-catenin regulation of the neuronal cytoskeleton. α N-catenin contains a putative F-actin-binding domain (ABD) at the C terminus. To assess the ability of α N-catenin to directly bind and bundle actin, we performed actin binding and bundling assays in vitro. Similar to the α -actinin control, full-length recombinant α N-catenin co-sedimented with F-actin ( Fig. 3a and Supplementary Fig. 11 ). Full-length α N-catenin appeared to weakly bundle F-actin filaments (Fig. 3b ), although more work is necessary to assess direct bundling activity. There was no noticeable change in the G-actin/F-actin ratio in NPCs from the control or affected patient ( Supplementary Fig. 12 ), arguing against an overall effect on actin stabilization.
Next, we generated lentiviral constructs lacking or containing amino acids 671-905, corresponding to the α N-catenin ABD 25 , and confirmed that encoded protein was stable in the NPCs ( Supplementary Fig. 8b ,c). CTNNA2 ΔABD could not rescue migration defects in the CTNNA2 KO neurons, and had no effect on control cells ( Fig. 3c and Supplementary Figs. 6 and 7). In contrast, expression of CTNNA2 ABD alone mediated rescue of migration in CTNNA2 KO , and enhanced migration in control neurons ( Fig. 3c and Supplementary Figs. 6 and 7). We conclude that the ABD of CTNNA2 is necessary and sufficient for its effect on neuronal migration in CTNNA2mutant cells.
The reduction in leading process stability we observed in CTNNA2-mutant neurons was similar to a phenotype recently described in mouse Arpc2-mutant radial glia 26 , suggesting that α N-catenin might regulate Arp2/3 activities. Recombinant α E-catenin controls actin-filament organization and represses Arp2/3-mediated actin polymerization in vitro 25 . Thus, we reasoned Letters NATuRE GENETics that the excessive filopodia formation, accompanied by repeated, rapid retraction of the leading process in CTNNA2-mutant neurons, might result from failure to suppress ARP2/3-mediated actin branching. To initiate actin branching, the ARP2/3 complex binds to the side of existing F-actin filaments to nucleate a new filament at a distinctive 70 o angle; consequently, ARP2 and ARP3 are incorporated into the microfilament structure 27 . To test for increased F-actin branching, we assessed the amount of ARP3 protein associated with F-actin filaments. Migrating neurons from the MDS patient showed ARP3 associated with actin to be equal to or less than in the control, whereas neurons from 1263A and CTNNA2 KO lines showed almost a 50% increase in association (Fig. 4a,c and Supplementary Fig.  13a,b ). We conclude that CTNNA2-deficient cells show excessive association between ARP2/3 and actin. ARP2/3 initiates actin branching in the presence of the WASP VCA (verprolin, cofilin, acidic) domain by the nucleation of F-actin filaments. Therefore, we tested whether α N-catenin was sufficient to inhibit the effect of ARP2/3 + VCA on actin polymerization. The recombinant VCA domain of human WASP (400 nM) showed minimal actin polymerizing activity. This was more than doubled upon 
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the addition of 10 nM ARP2/3 complex. Increasing concentrations of recombinant α N-catenin resulted in a dosage-dependent inhibition of the ARP2/3 + VCA effect on actin, reduced nearly back to baseline (Fig. 4b ). We conclude that α N-catenin is sufficient to suppress the effect of ARP2/3 + VCA on actin polymerization in vitro.
Since α N-catenin repressed ARP2/3 activity in vitro, we next tested whether this activity was mediated by the ABD using CTNNA2 KO neurons. We ectopically expressed the α N-catenin ABD and assessed the amount of ARP3 associated with actin by western blot. We observed a near doubling of ARP3 associated with F-actin, whereas expressing the α N-catenin ABD showed potent loss of most ARP3 bound to actin ( Fig. 4c and Supplementary Fig.  13b ), suggesting that the ABD domain of α N-catenin is sufficient to regulate ARP2/3-actin interaction. We also tested the ability of the recombinant α N-catenin ABD to repress ARP2/3-mediated actin polymerization in vitro. The ABD of α N-catenin was sufficient to repress ARP2/3-mediated actin polymerization in a dosage-depen-dent manner ( Supplementary Fig. 13c ), albeit to a lesser extent than full-length α N-catenin.
If α N-catenin mediates its effects on neuronal morphology through suppression of ARP2/3, inhibition of ARP2/3 should at least partially compensate for the loss of α N-catenin in neurons. To test this, we used two different cell-permeable ARP2/3 inhibitors, CK-666 and CK-869 (ref. 28 ), which inhibit ARP2/3 at different sites. After generating a dose-response curve, we analyzed neurite length in control, MDS, patient, and CTNNA2 KO migrating neurons after 24 h. Most of the control neurons showed long, extended bipolar neurites with an average length > 100 μ m. Both inhibitors showed a negative effect on neurite length in control neurons, but CTNNA2-mutant cells increased neurite length nearly tenfold, restoring the distribution to near control levels ( Fig. 4d and Supplementary Figs. 7 and 14) . MDS neurons showed neurites with an average length of 18 μ m, without improvement upon ARP2/3 inhibitor treatment. We conclude that ARP2/3 
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inhibitors can largely rescue the neurite length defect associated with loss of CTNNA2.
In summary, we have identified a new neuronal migration disorder due to biallelic truncating mutations in CTNNA2. The involvement of an actin regulator in pachygyria was surprising, given that previous genetic studies focused on microtubules 29 . Microtubules scaffold the cytoskeleton for the repeated cycles of migration 30, 31 . The main effect of actin appears to be in sensing and responding to extracellular guidance cues through changes in cell morphology, as well as guiding microtubules within the primary neurite 32 . This is mediated at least in part by calcium influx and enhanced neuronal motility through LIS1-dependent regulation of Rho GTPases 33 , but also through transmembrane proteins, which can alter the cell morphology through effects on actin 34 .
Actin structure is critically regulated by Arp2/3, which controls the decision to initiate branching. We show that Arp2/3 overactivity, as a result of loss of α N-catenin, leads to excessive branching, which impairs neurite growth and stability, possibly by controlling microtubule advance into the growth cone 32, 35 . α N-catenin suppresses actin branching; in vivo, this probably occurs by binding F-actin. This activity is mediated by the ABD, which we show competes with ARP2/3 for nucleation sites on F-actin. α -Actinin, fascin and α E-catenin can sort actin-associated proteins by altering the conformation of actin 1, 25, 36 . It will be interesting to determine whether α N-catenin also shares this property or whether it extends to other ABD-containing proteins. Thus, as a more general principle, actinbinding proteins may serve unrecognized roles in actin regulation by controlling F-actin polymerization as well as dictating actin conformation locally within a cell. 
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Methods Patient recruitment. Patients were enrolled and sampled according to protocols for standard local practice in approved human subjects at the respective institutions. Each subject was evaluated, and had MRI images taken, by one of the authors. We excluded cases with overlapping conditions such as asymmetrical brain dysplasia, primary white matter disease, or evidence of altered metabolism, such as elevations in lactate or abnormal peaks on standard clinical serum tandem mass spectroscopy.
Exome sequencing. For each sample, DNA was extracted from peripheral blood leukocytes by salt extraction. Exon capture was performed with the Agilent SureSelect Human All Exome 50 Mb Kit with paired-end sequencing on an Illumina HiSeq 2000 instrument, resulting in > 94% recovery at > 10× coverage.
Sequences were aligned to the human genome (hg19) with the Burrows-Wheeler Aligner, and variants were delineated using the Genome Analysis Toolkit software and SAMtools algorithms for both SNPs and insertion and deletion polymorphisms 8 . Variants were filtered for the criteria: (1) occurring in coding regions and/or splice sites; (2) non-synonymous; (3) found in less than 0.1% frequency in control populations (our in-house exome dataset of 12,000 individuals, Single Nucleotide Polymorphism database (dbSNP) and Exome Variant Server); (4) homozygous in consanguineous families; and (5) within linkage intervals or blocks of homozygosity. Variants were ranked by the type of mutation (nonsense/splice/indel > missense), amino acid conservation across species, and damage prediction programs (PolyPhen and Grantham score).
Linkage analysis.
All informative members of family 1101 were genotyped with the Infinium iSelect24 mapping panel (Center for Inherited Disease Research) and analyzed with easyLINKAGE-Plus software 37 . Parameters were autosomal recessive with full penetrance and a disease allele frequency of 0.001. Genomic regions with logarithm of the odds scores below -2 were excluded as loci, those above 2 were considered as candidate loci, and those above 3.3 were considered as statistical evidence for genome-wide significance. Linkage simulations were performed with Allegro 1.2c under the same parameters, with 5,000 markers at average intervals of 0.64 cM, co-dominant allele frequencies, and parametric calculations 37 .
Tissue culture. Fibroblasts were generated from unaffected and affected dermal biopsy explants and cultured in Minimum Essential Media (Gibco), supplemented with 20% fetal bovine serum (Gemini). iPSCs, neural progenitor cells, and neurons were obtained as previously described 19, 38 . MDS fibroblasts were obtained from the Coriell BioRepository (GM09209) and similarly reprogrammed.
iPSCs were generated as previously described 39 using 3 μ g expression plasmid mixtures (OCT3/4, SOX2, KLF4, L-MYC, LIN28, and p53 shRNA) electroporated into 6 × 10 5 cells. These were dissociated after 7 d, and 1.5 × 10 5 cells were re-plated onto 100 mm dishes with 1.5 × 10 5 irradiated CF-1 mouse embryonic fibroblasts as a feeder layer. Culture medium was replaced every day with hESC/iPSC medium (Dulbecco's modified Eagle medium/nutrient mixture F-12 (DMEM/ F12) supplemented with 20% knockout serum replacement and 20 ng ml -1 bFGF (Invitrogen), 1× non-essential amino acids, and 110 mM 2-mercaptoethanol). Colonies with healthy appearance (rounded smooth edges) were selected for further cultivation and evaluation. After three passages, iPSCs were transferred to Matrigel (BD Biosciences)-coated plates and grown in mTeSR medium (Stemcell Technologies).
NPCs were obtained as previously described 40 with embryoid bodies formed by mechanical dissociation of cell clusters and plated in suspension in differentiation medium (DMEM/F12, 1× N2, 1 μ M Dorsomorphin (Tocris Bioscience), and 2 μ M A8301 (Tocris Bioscience)) and shaken constantly at 95 r.p.m. for 7 d, then plated onto Matrigel (BD Biosciences)-coated dishes in NPC medium (DMEM/F12, 0.5× N2, 0.5× B27, and 20 ng ml -1 bFGF). Rosettes were visible after 5-7 d. They were selected with Neural Rosette Selection Reagent (Stemcell Technologies), and were NPCs plated onto poly-l-ornithine/laminin (Sigma) dishes with NPC medium, which was exchanged every 2 d.
Bright-field images were taken on Axio Vert.A1 or Axio Observer inverted microscopes (Zeiss), in addition to an EVOS microscope (Life Technologies), and processed using Photoshop CS5 (Adobe Systems). Time-lapse videos were acquired on a Zeiss Axio Observer and compiled with Zeiss ZEN software. Fluorescent confocal images of neural rosettes were taken on an LSM 880 (Zeiss) and processed using Fiji/ImageJ software. Images are maximum z projections of the entire depth of signal for the cell of interest.
CRISPR targeting. Frame-shifting insertions or deletions (indels), occurring in coding exon 12 of CTNNA2, were generated in H9 hESCs by CRISPR-SpCas9induced imprecise non-homologous end joining as previously described 41 with CTNNA2 sgRNA-F and CTNNA2 sgRNA-R primers ( Supplementary Table 1 ) into BbsI-digested px330. Individual colonies were isolated after two weeks, expanded, and genotyped by Sanger sequencing for biallelic mutations.
Complementary DNA synthesis and RT-PCR. Complementary DNA (cDNA) synthesis of 1 μ g patient RNA was performed using Superscript III First-Strand PCR with reverse transcription (RT-PCR) (Life Technologies). The reaction products were then used for quantitative real-time PCR (qRT-PCR) or cloning. qRT-PCR was performed in triplicate on 10 ng human cDNA for CTNNA2, AXIN2, ID2, LEF1, and GAPDH (see Supplementary Table 1 for primer sequences). Values were normalized to GAPDH as a loading control and the fold-change was calculated in reference.
Neurosphere assays. Neurosphere assay methods were modified from previously described protocols 42 . Three different stem cell lines (clones) per patient or condition were used as biological replicates for each experiment. The iPSC-derived NPCs were dissociated and incubated, shaking at 95 r.p.m, in NPC media. The following day, the media was changed to DMEM/F12 with 1× N2 and 1× B27, and shaking at 95 r.p.m for 12 h. The resultant neurospheres were plated on poly-lornithine/laminin plates, and imaged at 48 h to record the distance each neuronal cell body traveled from the edge of the neurosphere using Fiji/ImageJ (National Institutes of Health (NIH)) per clone. Data from each clone were collected and analyzed together with data from the other two clones per patient or condition to facilitate the statistical tests.
Neurite quantification. Three different stem cell lines (clones) per patient or condition were used as biological replicates for each experiment. To assess the leading process length, stem-cell-derived migrating neurons were imaged. The length of the primary neurite from the edge of the cell body to the tip of the growth cone was measured in micrometres. For ARP2/3 inhibition, 0.2 μ M CK-666, 0.2 μ M CK-869, or an equivalent dilution of DMSO was added to the neurons 6 h after plating 28 . Neurons were analyzed after 24 h. Data from each clone were collected and analyzed together with data from the other two clones per patient or condition to facilitate the statistical tests.
RNA sequencing. Total RNA was extracted from two NPC lines per patient with TRIzol Reagent (Gibco). Full-length messenger RNA was captured using a TruSeq Stranded mRNA kit (Illumina) with the standard protocol, and submitted for paired-end 100-nucleotide sequencing on MiSeq (Illumina). Roughly 30 million reads per sample were aligned to the 1000 Genomes Project's version of GRCh37 using standard TopHat2 (see URLs) v2.0.11 with paired-end read options and allowing for intron-spanning reads as defined by transcripts in Illumina iGenomes NCBI build 37.2. The pairwise Euclidean distance between all samples using the filtered (median fragments per kilobase of transcript per million mapped reads > 1) and log 2 -transformed gene expression values was calculated, and the Pearson's correlation was determined. Differential expression on a gene-based level was tested for with cuffdiff 59 v2.1.1 using the default option. Genes reported as significantly differentially expressed between a pair of conditions were determined based on a cuffdiff threshold of a false-discovery-rate-corrected P value of 0.05.
Histology. Animal use followed NIH guidelines and was approved by the Institutional Animal Care and Use Committee at the University of California, San Diego and Rockefeller University. Wild-type mice (C57BL/6N) were obtained from Jax and intercrossed to produce embryonic day E13.5 embryos. The embryos were fixed in 4% paraformaldehyde (PFA), cryoprotected, then sectioned. Human fetal brain was obtained from the University of California, San Diego autopsy service, fixed in 4% PFA and embedded in paraffin. Microtome sections were deparaffinized, blocked with 4% donkey serum, incubated in primary antibody overnight, washed, incubated in secondary antibody for 1 h, post-fixed in 4% PFA, and counterstained with 4′ ,6-diamidino-2-phenylindole or Nissl for imaging. αN-catenin lentivirus. Full-length, the ABD (amino acids 671-905) or ABDdeleted (Δ ABD; amino acids 1-670) α N-catenin was cloned into pLVX-AcGFP-N1 vector (Clontech) and co-transfected with psPAX2 and pCMV-VSVg (Addgene) into Lenti-X 293T cells (Clontech) to generate lentivirus. Virus-containing media was collected at 66 h, concentrated by ultracentrifuge, and stored at − 80 °C. Patient-derived NPCs were transduced with lentivirus and selected with 1 μ g ml -1 puromycin for 48 h before proceeding with the experiments.
Recombinant αN-catenin protein generation. cDNA encoding full-length α N-catenin was amplified and cloned into bacterial glutathione-S-transferase (GST) expression vector pGEX-6P-1 (GE Healthcare Life Sciences). Recombinant α N-catenin was produced in BL21 cells and affinity purified with anti-GST MagneGST beads (Promega).
Actin assays. Actin binding and bundling assays were performed according to the manufacturer's recommendations (BK001; Cytoskeleton). Actin polymerization assays were performed with pyrene actin (AP05; Cytoskeleton), α -actinin, the GST-tagged VCA domain of human WASP protein (#VCG03), and Arp2/3 protein complex from porcine brain (RP01P; Cytoskeleton) according to the manufacturer's recommendations, with the addition of recombinant α N-catenin. G-Actin/F-Actin ratios were determined in triplicate from patient-derived NPCs using the G-Actin/F-Actin In Vivo Assay Biochem Kit (BK037; Cytoskeleton). CK-666 and CK-869 block an activating conformational change, binding to different sites 28 . CK-666 stabilizes the inactive state of the complex, blocking movement of the Arp2 and Arp3 subunits into the activated filament-like (short Letters NATuRE GENETics pitch) conformation, while CK-869 binds to a serendipitous pocket on Arp3 and allosterically destabilizes the short-pitch Arp3-Arp2 interface.
F-actin pulldown. Phalloidin-mediated F-actin pulldown was performed as described 43 with Biotin-XX Phalloidin (B7474; Life Technologies) then streptavidin conjugated magnetic beads (Pierce Protein Biology), washed 3× , then boiled.
Antibodies. Primary antibodies used for immunocytochemistry or western blot include mouse anti-GAPDH (Millipore), mouse anti-Nestin (Millipore), mouse anti-Tuj1/β III-tubulin (Millipore), mouse anti-Tuj1/β III-tubulin (Santa Cruz Biotechnology), mouse anti-TRA-1-60 (Millipore), mouse anti-TRA-1-81 (Millipore), goat anti-Lin28a (R&D Systems), rabbit anti-Nanog (Santa Cruz Biotechnology), rabbit anti-Oct3/4 (Santa Cruz Biotechnology), rabbit anti-DCX 44 , goat anti-DCX (Santa Cruz Biotechnology), goat anti-SOX2 (Santa Cruz Biotechnology), rabbit anti-PAX6 (Covance), mouse anti-MAP2 (Millipore), mouse anti-BLBP (Abcam), rabbit anti-GFAP (Sigma), rabbit anti-OLIG2 (Abcam), mouse anti-β -Catenin (BD Biosciences), rabbit anti-Arp3 (Santa Cruz Biotechnology), mouse anti-β -actin (Sigma), rabbit anti-EIF3D (Bethyl Laboratoriess), rat anti-α N-catenin obtained from the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development Developmental Studies Hybridoma Bank (Catalog: NCAT2, deposited by M. Takeichi and S. Hirano). Fluorophore conjugated secondary antibodies were purchased from Invitrogen, and immunohistochemistry was performed with an ABC Elite Peroxidase Staining Kit, using ImmpactDAB as a substrate.
Statistics. Neuronal migration and neurite length were graphed in Microsoft
Excel as a box plot with quartile 1, the median, and quartile 3 displayed. Whiskers represent the maximum and minimum observed values for each comparison group across all replicates. Western blot densitometry and fold-change gene expression were plotted as a bar graph with the average of at least three replicates displayed, or the values displayed on the figure. Error bars represent the s.e. of the mean. Unpaired, two-tailed Student's t-tests were used to calculate significance (*P < 0.05; **P < 0.001; ***P < 0.0001; NS, not significant). Figure 2a : control versus MDS, P = 3.29 × 10 −34 ; control versus 1263A, P = 1.20 × 10 −27 ; control versus CTNNA2 KO , P = 1.01 × 10 −18 . Figure 2b : control versus 1263A, P = 2.74 × 10 −26 ; control versus CTNNA2 KO , P = 4.03 × 10 −57 ; control versus control + CTNNA-GFP, P = 2.64 × 10 −7 ; 1263A versus 1263A + CTNNA-GFP, P = 4.30 × 10 −26 ; CTNNA2 KO versus CTNNA2 KO + CTNNA-GFP, P = 1.66 × 10 −59 ; control versus 1263A + CTNNA-GFP, P = 0.04; control versus CTNNA2 KO + CTNNA-GFP, P = 0.73. Figure 3c : control versus control + CTNNA-GFP, P = 0.29; CTNNA2 KO versus CTNNA2 KO + CTNNA-GFP, P = 1.15 × 10 −21 ; control versus CTNNA2 KO + CTNNA-GFP, P = 0.10. Figure 3c : control versus control + CTNNA ΔABD , P = 0.65; control versus control + CTNNA ABD , P = 2.68 × 10 −21 ; CTNNA2 KO versus CTNNA2 KO + CTNNA ΔABD , P = 0.06; CTNNA2 KO versus CTNNA2 KO + CTNNA ABD , P = 1.81 × 10 −30 . Figure  4c : control versus control + CK-666, P = 3.37 × 10 −3 ; MDS versus MDS + CK-666, P = 0.29; 1263A versus 1263A + CK-666, P = 5.75 × 10 −19 ; CTNNA2 KO versus CTNNA2 KO + CK-666, P = 3.48 × 10 −52 ; control versus MDS + CK-666, P = 2.12 × 10 −53 ; control versus 1263A + CK-666, P = 0.03; control versus CTNNA2 KO + CK-666, P = 4.86 × 10 −10 . Supplementary Fig. 4 : control versus 1263A, P = 0.003; no detectable protein in CTNNA2 KO . Supplementary Fig. 8 : AXIN2 control versus 1263A, P = 0.81; ID2 control versus 1263A, P = 0.53; LEF1 control versus 1263A, P = 0.32. Supplementary Fig. 10 : control versus 1263A, P = 0.35. Supplementary Fig. 11 : control versus control + CK-869, P = 1.88 × 10 −17 ; MDS versus MDS + CK-869, P = 2.47 × 10 −5 ; 1263A versus 1263A + CK-869, P = 1.18 × 10 −38 ; CTNNA2 KO versus CTNNA2 KO + CK-869, P = 5.47 × 10 −57 ; control versus MDS + CK-869, P = 1.47 × 10 −61 ; control versus 1263A + CK-869, P = 5.22 × 10 −6 ; control versus CTNNA2 KO + CK-666, P = 0.26. Corresponding author(s): Gleeson, Joseph G
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Experimental design 1. Sample size
Describe how sample size was determined. LOD scores were estimated using Allegro experiments were run with biological replicates in triplicate.
Data exclusions
Describe any data exclusions.
No data was excluded. No other families from our cohort had rare (<0.1% AF) predicted deleterious variants in CTNNA2.
Replication
Describe whether the experimental findings were reliably reproduced. 
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No randomization was performed.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Data collection and analysis was not performed blinded.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance. Describe the software used to analyze the data in this study.
EasyLinkage (running Allegro), Excel (statistical analysis)
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Describe any restrictions on availability of unique materials used in the study OR confirm that all unique materials used are readily available from the authors or from standard commercial sources (and specify these sources) OR state that no unique materials were used.
